Updated on 19 August 2013
Tianyin Pharmaceutical has been awarded the good manufacturing practices (GMP) renewal status for the next three years through 2015
Singapore: China's Tianyin Pharmaceutical, a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), has been awarded the good manufacturing practices (GMP) renewal status for the next three years through 2015.
The new GMP standards, issued in 2011, provides specification for pharmaceutical manufacturing facility in general provisions, quality management (quality assurance, quality control and quality risk management), organization and personnel, premises and facilities, equipment, materials and production, qualification and validation, documentation management, production management, quality control and quality assurance, contract manufacture and analysis, product distribution and recalls, self inspections, and supplementary provisions.
After the inspection by the China Food and Drug Administration (CFDA) officials in month of July, the company received the confirmation that the facility has been awarded GMP renewal status. TPI expects to receive the official certificate at the end of August 2013.